Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention

Matteo Nicola Dario Di Minno, Anna Guida, Marina Camera, Susanna Colli, Giovanni Di Minno, Elena Tremoli

Research output: Contribution to journalArticle

Abstract

Platelets play a central role in the pathophysiology of atherothrombosis, an inappropriate platelet activation leading to acute ischemic complications (acute myocardial infarction, ischemic stroke). In view of this, platelets are a major target for pharmacotherapy. Presently, the main classes of antiplatelet agents approved for the use in such complications are aspirin and thienopyridines. Although antiplatelet treatment with these two types of drugs, alone or in combination, leads to a significant reduction of non-fatal myocardial infarction (-32%), non-fatal stroke (-25%), and of cardiovascular death (-17%), a residual risk persists. Newer antiplatelet agents have addressed some, but not all, these limitations. Vis - vis their net clinical benefit, the higher potency of some of them is associated with a rise in bleeding complications. Moreover, newer thienopyridines do not show advantages over and above the older ones as to reduction of stroke. A concerted effort that takes into consideration clinical, genetic, and laboratory information is increasingly recognized as a major direction to be pursued in the area. The well-established road signs of clinical epidemiology will provide major information to define newer potentially useful targets for platelet pharmacology.

Original languageEnglish
Pages (from-to)531-544
Number of pages14
JournalAnnals of Medicine
Volume43
Issue number7
DOIs
Publication statusPublished - Nov 2011

    Fingerprint

Keywords

  • Aspirin failure
  • Cardiovascular prevention
  • Clopidogrel failure
  • New antiplatelet drugs

ASJC Scopus subject areas

  • Medicine(all)

Cite this